comment
research
note
common
featur
pharmacophor
fdaapprov
drug
inhibit
ebola
viru
ref
statu
index
current
face
global
infecti
diseas
crisi
anticip
decad
mani
promis
biotherapeut
test
search
small
molecul
yet
deliv
approv
drug
therapeut
ebola
similar
filovirus
caus
haemorrhag
fever
two
recent
high
throughput
screen
publish
howev
identifi
sever
hit
progress
anim
studi
fda
approv
drug
use
indic
current
comput
analysi
use
molecul
two
differ
structur
class
construct
common
featur
pharmacophor
ligandbas
pharmacophor
implic
possibl
common
target
mechan
could
explor
recent
structur
base
design
project
yield
nine
cocryst
structur
pyrrolidinon
inhibitor
bound
viral
protein
receptorligand
pharmacophor
base
analog
molecul
protein
structur
construct
molecular
featur
partial
overlap
common
featur
sole
ligandbas
pharmacophor
model
base
fda
approv
drug
previous
identifi
fda
approv
drug
activ
ebola
therefor
dock
protein
antimalari
chloroquin
amodiaquin
dock
favor
propos
drug
identifi
date
inhibitor
ebola
viru
may
target
comput
model
may
provid
preliminari
insight
molecular
featur
respons
activ
ebola
viru
propos
hypothesi
could
readili
test
vitro
vivo
current
ebola
viru
ebov
crisi
demonstr
global
prepar
respond
therapeut
treat
exist
infect
act
prophylact
food
drug
administr
fda
european
medicin
agenc
emea
approv
therapeut
importantli
suggest
prepar
pathogen
known
nearli
forti
year
current
ebov
outbreak
alreadi
prove
remark
costli
term
mortal
financi
ramif
best
approach
ebov
far
reli
public
health
measur
contain
use
past
outbreak
lesson
ebov
undoubtedli
import
next
viru
outbreak
also
rais
mani
question
point
littl
know
virus
gener
well
best
share
knowledg
openli
rel
small
number
studi
attempt
identifi
compound
activ
ebov
two
recent
studi
util
highthroughput
screen
subset
fda
approv
drug
differ
ebov
strain
zair
sudan
vitro
vivo
independ
report
suggest
promis
antimalari
amodiaquin
chloroquin
one
studi
select
estrogen
receptor
modul
serm
clomiphen
toremifen
activ
anoth
chloroquin
date
progress
beyond
mous
ebov
model
use
studi
hypothes
could
use
four
molecul
comput
defin
featur
import
activ
previou
studi
exhaust
screen
fda
drug
taken
opportun
suggest
addit
compound
look
anoth
perspect
nonantivir
drug
may
worth
follow
even
though
molecular
mechan
unknown
compound
may
broad
antivir
activ
report
describ
modest
inhibitori
activ
virus
sever
studi
identifi
nonfda
approv
drug
includ
silico
dock
approach
identifi
molecul
target
viral
interfac
molecul
similar
fda
benzimidazol
aminoquinolin
compound
activ
ebov
anoth
good
exampl
recent
silico
dock
million
druglik
compound
dock
viral
protein
protein
identifi
multipl
pyrrolidinon
inhibit
polymeras
cofactor
activ
pyrrolidinon
bind
alpha
helix
propos
import
viral
function
limit
knowledg
small
molecul
potenti
target
studi
whether
fdaapprov
drug
activ
vitro
vivo
versu
ebov
could
target
common
featur
pharmacophor
ebov
activ
two
paper
describ
compound
activ
inhibitor
differ
ebov
strain
vitro
vivo
name
amodiaquin
chloroquin
one
studi
clomiphen
toremifen
anoth
activ
molecul
use
vitro
vivo
activ
build
common
featur
pharmacophor
discoveri
studio
biovia
san
diego
ca
conform
molecul
gener
caesar
algorithm
identifi
key
featur
pharmacophor
use
search
variou
databas
molecul
conform
fast
conform
gener
method
maximum
energi
threshold
kcalmol
creat
pharmacophor
use
search
microsourc
spectrum
databas
http
wwwmsdiscoverycomspectrumhtml
well
cdd
fda
drug
dataset
http
wwwcollaborativedrugcom
pagespublicaccess
case
hit
retriev
initi
van
der
waal
surfac
amodiaquin
potent
chloroquin
ad
limit
number
hit
retriev
receptorligand
pharmacophor
protein
gener
crystal
structur
protein
data
bank
pdb
pharmacophor
construct
use
receptorligand
pharmacophor
gener
protocol
discoveri
studio
version
biovia
san
diego
ca
maximum
number
pharmacophor
minimum
featur
maximum
number
featur
describ
elsewher
silico
dock
molecul
structur
pdb
use
dock
use
libdock
discoveri
studio
biovia
san
diego
ca
propos
bind
site
center
ligand
site
sphere
creat
coordin
diamet
protocol
includ
hotspot
dock
toler
fast
conform
method
also
use
along
steepest
descent
minim
charmm
paramet
follow
default
set
ligand
remov
bind
site
redock
four
fda
approv
drug
activ
ebola
dock
structur
sdf
file
molecul
visual
alongsid
origin
ligand
interact
plot
gener
common
featur
pharmacophor
ebov
activ
pharmacophor
gener
use
vivo
vitro
activ
amodiaquin
chloroquin
clomiphen
toremifen
respond
review
suggest
made
small
label
addit
figur
ad
new
figur
expand
view
figur
supplement
tabl
repres
relev
fda
approv
drug
date
pharmacophor
consist
hydrophob
featur
hydrogen
bond
acceptor
featur
figur
pharmacophor
van
der
waal
surfac
also
use
search
fda
drug
variou
librari
supplement
tabl
supplement
tabl
interest
observ
virtual
screen
variou
estradiol
analog
score
well
eg
estradiol
valer
fit
valu
previous
estradiol
suggest
activ
ebov
pseudotyp
assay
vitro
addit
dibucain
also
retriev
fit
valu
also
activ
ebov
pseudotyp
assay
amodiaquin
chloroquin
clomiphen
toremifen
use
posit
control
futur
screen
origin
complet
set
fda
approv
compound
screen
public
access
difficult
compar
hit
rate
versu
compound
test
date
nine
receptorligand
pharmacophor
creat
consist
three
four
hydrophob
featur
one
two
hydrogen
bond
featur
tabl
eight
pharmacophor
also
neg
ioniz
featur
suggest
receptorligand
base
approach
result
gener
similar
across
nine
structur
like
indic
similar
bind
mode
import
featur
interf
gener
hydrophob
pocket
proteinprotein
interact
silico
dock
molecul
structur
redock
ligand
protein
result
rmsd
gener
indic
difficulti
predict
orient
compound
bind
rel
hydrophob
shallow
pocket
figur
molecul
rank
th
pose
libdock
score
figur
higher
score
better
four
fda
approv
drug
dock
structur
compound
dock
similarli
overlap
cocryst
ligand
figur
amodiaquin
chloroquin
higher
libdock
score
ligand
clomiphen
toremifen
libdock
score
less
four
fda
approv
drug
bound
similarli
pyrrolidinon
ligand
pocket
form
residu
subdomain
highlight
propos
energet
favor
interact
antimalari
candid
binder
score
favor
previous
publish
studi
suggest
mutat
result
nearcomplet
loss
bind
activ
previou
experi
common
featur
quantit
pharmacophor
model
demonstr
valu
predict
novel
activ
collect
fda
approv
drug
candid
predict
activ
may
assess
fit
valu
pharmacophor
model
score
use
priorit
compound
eventu
test
current
studi
hypothes
two
differ
class
compound
show
activ
ebov
vitro
vivo
may
share
common
pharmacophor
construct
pharmacophor
figur
indic
four
hydrophob
featur
hydrogen
bond
acceptor
featur
pharmacophor
ad
van
der
waal
surfac
limit
number
hit
retriev
use
screen
score
fda
drug
score
particularli
well
term
dock
case
could
provid
mean
follow
small
molecul
analog
andor
addit
fda
approv
drug
could
target
proteinprotein
interact
tuberculosisfocus
research
comput
approach
reposit
compound
embrac
essenti
comput
predict
interrog
rigor
experiment
studi
exampl
least
two
silico
dock
studi
screen
commerci
avail
compound
propos
dock
fda
approv
drug
could
also
viabl
first
step
identifi
potenti
compound
could
use
activ
seek
collabor
experi
ebov
assay
enabl
translat
studi
believ
comput
inspir
approach
may
applic
known
infecti
pathogen
current
treatment
virus
relat
ebola
ultim
need
abl
leverag
approach
provid
antivir
futur
pathogen
dataset
pharmacophor
receptor
ligand
model
dock
data
fdaapprov
drug
inhibit
ebola
viru
ligandbas
pharmacophor
previous
made
avail
http
figsharecomarticlesebolaactivecpdspharmacophor
follow
pdb
structur
use
studi
model
advic
pleas
contact
sean
ekin
ekinssean
yahoocom
author
contribut
se
mc
came
gener
idea
studi
base
publish
vitro
vivo
data
author
contribut
collabor
write
project
se
work
collabor
chemistri
consult
collabor
drug
discoveri
inc
author
declar
grant
involv
support
work
dr
christoph
southan
dr
peter
madrid
dr
nadia
litterman
acknowledg
discuss
ebola
biovia
kindli
acknowledg
provid
discoveri
studio
earlier
preliminari
version
pharmacophor
describ
previous
http
figsharecomarticlesapharmacophoreofebolaact
small
databas
identifi
structur
futur
evalu
vitro
test
supplement
tabl
supplement
tabl
compound
estradiol
dibucain
previous
describ
activ
vitro
ebov
assay
suggest
pharmacophor
could
retriev
structur
divers
class
known
hit
recent
identifi
cocryst
structur
ebov
protein
use
deriv
receptorligand
pharmacophor
nine
receptorligand
pharmacophor
suggest
import
hydrophob
hydrogen
bond
neg
ioniz
interact
interfer
proteinprotein
interact
tabl
eight
nine
pharmacophor
one
hydrogen
bond
acceptor
featur
pharmacophor
grossli
similar
ligand
base
pharmacophor
deriv
four
fda
approv
drug
inhibit
ebov
type
model
multipl
hydrophob
featur
least
one
hydrogen
bond
acceptor
dock
antimalari
serm
repres
structur
compound
found
overlap
xray
ligand
differ
extent
amodiaquin
chloroquin
libdock
score
greater
higher
redock
xray
ligand
indic
may
potenti
target
two
distinct
class
compound
howev
import
point
compar
dock
protein
ebov
could
also
possibl
molecul
activ
elsewher
well
via
mechan
specif
bind
protein
may
prefer
target
antimalari
serm
predict
bind
well
xray
ligand
use
dock
score
method
may
produc
differ
pose
predict
bind
affin
could
interest
studi
combin
promis
efficaci
chloroquin
ec
amodiaquin
ec
versu
ebov
avail
like
low
cost
priorit
laboratori
explor
mechanist
studi
possibl
protein
also
pursu
may
enlighten
observ
compound
also
report
activ
virus
exampl
chloroquin
activ
human
coronaviru
vitro
infect
mice
well
sar
vitro
amodiaquin
also
inhibit
dengu
viru
replic
infect
vitro
summari
studi
built
previou
public
identifi
four
fda
approv
compound
activ
differ
strain
ebov
pharmacophor
model
serm
aminoquinolin
suggest
compound
share
multipl
chemic
featur
base
overlap
four
hydrophob
featur
hydrogen
bond
acceptor
figur
may
common
mechan
target
suggest
may
like
target
base
overlap
receptorbas
pharmacophor
dock
crystal
structur
amodiaquin
chloroquin
figur
redock
ligand
remov
structur
redock
closest
pose
grey
rank
rmsd
libdock
score
compar
actual
ligand
yellow
tabl
fda
drug
common
featur
pharmacophor
dataset
molecul
download
cdd
public
access
http
wwwcollaborativedrugcompagespublicaccess
sdf
databas
creat
discoveri
studio
use
fast
conform
gener
conform
databas
search
common
featur
pharmacophor
develop
amodiaquin
chloroquin
clomiphen
toremifen
search
databas
protocol
use
fast
search
method
case
indic
molecul
describ
nd
tabl
microsourc
spectrum
common
featur
pharmacophor
dataset
molecul
provid
microsourc
http
wwwmsdiscoverycomspectrumhtml
sdf
databas
creat
discoveri
studio
use
fast
conform
gener
conform
databas
search
common
featur
pharmacophor
develop
amodiaquin
chloroquin
clomiphen
toremifen
search
databas
protocol
use
fast
search
method
present
crisp
lucid
manuscript
relev
topic
suggest
et
al
methodolog
extract
common
featur
four
approv
compound
recent
found
work
ebola
viru
amodiaquin
chloroquin
clomiphen
toremifen
defin
pharmacophor
use
search
databas
identifi
compound
vitro
vivo
test
methodolog
describ
provid
excel
method
quickli
screen
known
silico
compound
possibl
therapi
ebola
particular
virus
gener
result
serm
show
lower
score
bind
ration
find
clomiphen
toremifen
inhibit
ebov
vlp
entri
specif
gp
therefor
probabl
inhibit
chloroquin
date
progress
beyond
mous
ebov
model
use
studi
statement
clear
mean
other
progress
beyond
mous
ebov
model
first
compound
supplement
tabl
part
main
manuscript
tabl
color
code
pharmacophor
featur
fig
come
earlier
tabl
describ
structur
look
better
white
background
rmsd
redock
given
ligand
quit
high
author
consid
use
dock
method
comparison
tabl
libdock
score
would
help
easili
analyz
result
mention
whether
higher
score
better
signific
score
major
concern
manuscript
use
proprietari
softwar
data
format
studi
make
difficult
user
probe
result
dock
structur
nonstandard
format
subject
exist
compani
use
given
futur
respons
data
avail
easili
websit
see
benefit
take
compound
supplement
tabl
put
bodi
manuscript
might
also
add
confus
cut
tabl
color
code
pharmacophor
featur
fig
come
earlier
tabl
describ
respons
thank
ad
respons
think
person
prefer
structur
clear
opinion
black
background
suggest
previous
public
regard
background
color
studi
intend
exhaust
dock
comparison
plenti
literatur
note
review
agre
redock
rmsd
high
also
provid
justif
result
difficulti
predict
orient
compound
bind
rel
hydrophob
shallow
pocket
other
want
use
differ
method
perform
comparison
target
would
support
tabl
libdock
score
would
help
easili
analyz
result
mention
whether
higher
score
better
signific
score
libdock
score
best
pose
libdock
dock
data
best
pose
file
higher
score
better
ad
result
section
major
concern
manuscript
use
proprietari
softwar
data
format
studi
make
difficult
user
probe
result
dock
structur
nonstandard
format
subject
exist
compani
use
given
futur
model
gener
proprietari
softwar
discoveri
studio
respons
file
provid
comment
softwar
true
support
use
open
softwar
yet
find
open
sourc
pharmacophor
tool
good
discoveri
studio
date
also
conveni
use
softwar
gener
pharmacophor
receptorligand
pharmacophor
dock
place
type
analysi
describ
could
repeat
softwar
open
sourc
proprietari
hope
make
work
openli
access
other
inspir
pursu
comput
approach
ebov
perhap
commun
could
propos
use
standard
open
pharmacophor
file
well
publish
journal
make
data
open
even
though
proprietari
format
think
preclud
public
compet
interest
disclos
current
ebola
crisi
west
africa
shatter
expect
continu
grow
month
follow
initi
case
stimul
massiv
global
emerg
respons
challeng
health
protocol
extens
effort
scientif
commun
author
carri
comput
analysi
use
sever
compound
detect
two
previou
high
throughput
screen
build
pharmacophor
model
key
featur
model
use
scan
databas
small
molecul
come
list
put
inhibitor
studi
stronger
scientif
impact
author
could
elabor
suggest
best
rank
compound
increas
bind
affin
base
structur
model
built
parallel
observ
highli
overlap
motif
pharmacophor
found
crystal
structur
sever
inhibitor
viral
protein
base
fact
result
insilico
dock
propos
like
inhibitori
mechan
compound
target
proteinprotein
interact
involv
protein
regard
author
extend
studi
includ
differ
dock
protocol
includ
differ
program
attempt
verifi
result
mention
text
page
redock
ligand
protein
show
crystal
structur
bind
mode
accur
differ
set
could
help
better
predict
ligand
orient
concern
dock
propos
mechan
wonder
differ
solv
nucleocapsid
protein
structur
sequenc
point
view
order
make
author
point
inde
target
would
possibl
explor
surfac
patch
similar
physicochem
featur
case
potenti
bind
pocket
smallmolecul
inhibitor
suggest
good
bad
overlap
built
pharmachophor
hartlieb
et
al
case
complet
structur
understand
action
compound
figur
display
locat
protein
surfac
well
bind
site
rna
would
clarifi
role
inhibit
proteinprotein
interact
summari
manuscript
describ
interest
fast
approach
identifi
put
inhibitor
current
seriou
target
ebola
viru
although
result
experiment
valid
confirm
find
comput
studi
extens
great
valu
compet
interest
disclos
current
ebola
crisi
west
africa
shatter
expect
continu
grow
month
follow
initi
case
stimul
massiv
global
emerg
respons
challeng
health
protocol
extens
effort
scientif
commun
author
carri
comput
analysi
use
sever
compound
detect
two
previou
high
throughput
screen
build
pharmacophor
model
key
featur
model
use
scan
databas
small
molecul
come
list
put
inhibitor
studi
stronger
scientif
impact
author
could
elabor
suggest
best
rank
compound
increas
bind
affin
base
structur
model
built
respons
clarifi
focus
awar
xray
structur
ligand
bound
type
approach
could
certainli
pursu
ebov
target
produc
common
featur
pharmacophor
compound
look
receptorligand
pharmacophor
propos
may
overlap
led
dock
compound
xray
structur
intent
design
molecul
use
avail
method
perhap
infer
potenti
targetmechan
perhap
research
would
want
test
compound
access
experiment
test
predict
manuscript
may
lead
other
work
perhap
whether
one
want
use
libdock
score
absolut
predict
bind
affin
interact
debat
rather
approach
might
help
limit
priorit
compound
test
parallel
observ
highli
overlap
motif
pharmacophor
found
crystal
structur
sever
inhibitor
viral
protein
base
fact
result
insilico
dock
propos
like
inhibitori
mechan
compound
target
proteinprotein
interact
involv
protein
respons
may
target
compound
although
discount
target
nontarget
relat
mechan
regard
author
extend
studi
includ
differ
dock
protocol
includ
differ
program
attempt
verifi
result
mention
text
page
redock
ligand
protein
show
crystal
structur
bind
mode
accur
differ
set
could
help
better
predict
ligand
orient
respons
explain
earlier
studi
intend
exhaust
evalu
dock
tool
use
differ
comput
approach
suggest
fda
drug
may
common
pharmacophor
seem
similar
ligand
cocrystal
final
dock
suggest
may
fit
pocket
cocryst
ligand
bind
work
propos
compound
could
fit
bind
site
unclear
addit
valu
dock
would
add
unless
go
tri
predict
gener
xray
structur
fda
drug
certainli
expert
dock
crystallographi
want
pursu
target
